Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor

Clinical Characteristics, Treatment Patterns and Outcomes in Patients With axSpA and PsA Following Initiation of Bimekizumab, Risankizumab, Guselkumab, Upadacitinib or a TNF Inhibitor

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.

Who May Be Eligible (Plain English)

Who May Qualify: - Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA). - Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA. - Participant is aged 18 years or older at enrolment. Who Should NOT Join This Trial: -Participation in a clinical trial at enrolment. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA). * Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA. * Participant is aged 18 years or older at enrolment. Exclusion Criteria: -Participation in a clinical trial at enrolment.

Treatments Being Tested

OTHER

observational study

This is an observational study based on existing treatments prescribed prior to inclusion. No interventions are given as part of this research.

Locations (1)

Royal National Hospital for Rheumatic Diseases
Bath, Somerset, United Kingdom